Form 4: Ultragenyx EVP Karah Parschauer Reports Stock Transactions

Karah Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of common stock and stock options.

Summary

• On March 1, 2024, Karah Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., reported transactions involving the company's common stock and stock options.
• Parschauer acquired 17,800 shares of common stock through an award of Restricted Stock Units (RSUs) under the company's 2023 Incentive Plan, vesting in equal installments over four years.
• Additionally, 957 shares were acquired through the conversion of previously granted performance stock units upon certification of the performance metric on the same date.
• Parschauer sold 3,756 shares at $53.76 per share to cover required tax withholdings due to the vesting of RSUs.
• A stock option to buy 31,400 shares at an exercise price of $53.69 was also acquired, vesting over four years from the grant date.
• Following these transactions, Parschauer beneficially owns 67,340 shares of common stock and 31,400 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs and stock options is a positive sign, indicating confidence in the company's future. The sale of shares to cover taxes is a neutral event.

Positives

• The grant of RSUs and stock options to a key executive suggests a continued investment in and alignment with the company's long-term success.
• The conversion of performance stock units indicates that performance metrics were met, which is a positive signal.

Negatives

• The sale of shares to cover tax withholdings, while common, slightly reduces the executive's stake in the company.

Future Outlook

The RSUs and stock options vest over time, aligning the executive's interests with the company's long-term performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the pharmaceutical industry to incentivize executives.
• Vesting schedules of four years are typical for such grants.
• Comparing the size of the grants to those of executives at similar-sized biotech companies (e.g., BioMarin, Sarepta) would provide further context.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of alignment between management and shareholder interests.
• Employees may be motivated by the company's investment in its executives.

Key Dates